Amplified release through the stimulus triggered degradation of self-immolative oligomers, dendrimers, and linear polymers

Advanced Drug Delivery Reviews

Volumn 64, Issue 11, 2012, Pages 1031-1045

  Wong, Andrew D ^a   DeWit, Matthew A ^a   Gillies, Elizabeth R ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Biodegradable polymers; Cascade reactions; Depolymerization; Drug delivery; Nanoparticles; Prodrugs; Sensors

Indexed keywords

BIOLOGICAL SIGNALS; CASCADE REACTIONS; DELIVERY SYSTEMS; DRUG DELIVERY VEHICLES; DRUG MOLECULES; INTRAMOLECULAR REACTIONS; LINEAR POLYMERS; MOLECULAR FRAGMENTATION; NANO SCALE; PHYSIOLOGICAL CONDITION; PRODRUGS; RELEASE STRATEGIES; THERAPEUTIC TARGETS;

BIODEGRADABLE POLYMERS; DEGRADATION; DENDRIMERS; DEPOLYMERIZATION; DRUG DELIVERY; NANOPARTICLES; OLIGOMERS; SENSORS; TISSUE;

MOLECULES;

1,3 PROPANEDIOL; 2 (4 AMINOBENZYLIDENE)PROPANE 1,3 DIOL; 4 NITROANILINE; CAMPTOTHECIN; DENDRIMER; DOXORUBICIN; ETOPOSIDE; LIPOSOME; MACROGOL; MELPHALAN; NANOPARTICLE; OLIGOMER; PACLITAXEL; PENICILLIN AMIDASE; POLYMER; PRODRUG; UNCLASSIFIED DRUG;

BIODEGRADATION; BIOSENSOR; CANCER CELL CULTURE; CYCLIZATION; CYTOTOXICITY TEST; DECARBOXYLATION; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG RELEASE; DRUG RESEARCH; DRUG STRUCTURE; HUMAN; NANOANALYSIS; NANOPHARMACEUTICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW;

DRUG DELIVERY SYSTEMS; DRUG DESIGN; POLYMERS;

EID: 84864512974     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2011.09.012     Document Type: Review

References (128)

1. Doshi N., Mitragotri S. Designer biomaterials for nanomedicine. Adv. Funct. Mater. 2009, 19:3843-3854.
2. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf. B. 2010, 75:1-18.
3. Mikhail A.S., Allen C. Block copolymer micelles for delivery of cancer therapy: Transport at the whole body, tissue and cellular levels. J. Control. Release 2009, 138:214-223.
4. Torchilin V.P. Polymeric micelles for therapeutic applications in medicine. Nano Sci. Nano Technol. 2010, 9:261-299.
5. Souto E.B., Müller R.H. Lipid nanoparticles: effect on bioavailability and pharmacokinetic changes. Drug Delivery 2010, 115-142. Springer-Verlag, Heidelberg. M. Schäfer-Korting (Ed.).
6. Shailesh S., Neelam S., Sandeep K., Gupta G.D. Liposomes: a review. J. Pharm. Res. 2009, 2:1163-1167.
7. Meng F., Engbers G.H.M., Feijen J. Biodegradable polymersomes as a basis for artificial cells: encapsulation, release and targeting. J. Control. Release 2005, 101:187-198.
8. Christian D.A., Cai S., Bowen D.M., Kim Y., Pajerowski J.D., Discher D.E. Polymersome carriers: From self-assembly to siRNA and protein therapeutics. Eur. J. Pharm. Biopharm. 2009, 71:463-474.
9. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 2006, 6:688-701.
10. Vincent M.J., Ringsdorf H., Duncan R. Polymer therapeutics: clinical applications and challenges for development. Adv. Drug Deliv. Rev. 2009, 61:1117-1120.
11. Gillies E.R., Fréchet J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 2005, 10:35-43.
12. Lee C.C., MacKay J.A., Fréchet J.M.J., Szoka F.C. Designing dendrimers for biological applications. Nat. Biotechnol. 2005, 23:1517-1526.
13. W. Wijagkanalan, S. Kawakami, M. Hashida, Designing dendrimers for drug delivery and imaging: pharmacokinetic considerations, Pharm. Res. in press.
14. Hefferman M.J., Murthy N. Polyketal nanoparticles: a new pH-sensitive biodegradable drug delivery vehicle. Bioconjug. Chem. 2005, 16:1340-1342.
15. Jain R., Standley S.M., Frechet J.M.J. Synthesis and degradation of pH-sensitive linear poly(amidoamine)s. Macromolecules 2007, 40:452-457.
16. Murthy N., Thng Y.X., Schuck S., Xu M., Frechet J.M.J. A novel strategy for encapsulation and release of proteins: hydrogels and microgels with acid-labile acetal cross-linkers. J. Am. Chem. Soc. 2002, 124:12398-12399.
17. Meng F., Zhong Z., Feijen J. Stimuli-responsive polymersomes for programmed drug delivery. Biomacromolecules 2009, 10:197-209.
18. Bae Y., Fukushima S., Harada A., Kataoka K. Design of environment-sensitive supramolecular assemblies for intracellular drug delivery: polymeric micelles that are responsive to intracellular pH change. Angew. Chem. Int. Ed. 2003, 42:4640-4643.
19. Gillies E.R., Fréchet J.M.J. pH-Responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. 2005, 16:361-368.
20. Gillies E.R., Fréchet J.M.J. Development of acid sensitive copolymer micelles for drug delivery. Pure Appl. Chem. 2004, 76:1295-1308.
21. Bikram M., West J.L. Thermo-responsive systems for controlled drug delivery. Expert Opin. Drug Deliv. 2008, 5:1077-1091.
22. Liu R., Fraylich M., Saunders B.R. Thermoresponsive polymers: from fundamental studies to applications. Colloid Polym. Sci. 2009, 287:627-643.
23. Takae S., Miyata K., Oba M., Ishi T., Nishiyama N., Itaka K., Yamasaki Y., Koyama H., Kataoka K. PEG-detachable polyplex micelles based on disulfide-linked block catiomers as bioresponsive nonviral gene vectors. J. Am. Chem. Soc. 2008, 130:6001-6009.
24. Kakizawa Y., Harada A., Kataoka K. Glutathione-sensitive stabilization of block copolymer micelles composed of antisense DNA and thiolated poly(ethylene glycol)-block-poly(L-lysine): A potential carrier for systemic delivery of antisense DNA. Biomacromolecules 2001, 2:491-497.
25. Emiltiri E., Ranucci E., Ferruti P. New poly(amidoamine)s containing disulfide linkages in their main chain. J. Polym. Sci. Part A: Polym. Chem. 2005, 43:1404-1416.
26. Christensen L.V., Chang C.-W., Kim W.-J., Kim S.W., Zhong Z., Lin C.C., Engbersen J.F.J., Feijen J. Reducible poly(amido ethyleneimine)s designed for triggered intracellular gene delivery. Bioconjug. Chem. 2006, 17:1233-1240.
27. Meng F., Hennick W.E., Zhong Z. Reduction-sensitive polymers and bioconjugates for biomedical applications. Biomaterials 2009, 30:2180-2198.
28. Kuppusamy P., Li H., Ilangovan G., Cardounel A.J., Zweier J.L., Yamada K., Krishna M.C., Mitchell J.B. Noninvasive imaging of tumor redox status and its modification by tussue glutathione levels. Cancer Res. 2002, 62:307-312.
29. Saito G., Swanson J.A., Lee K.D. Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 2003, 55:199-215.
30. Engin K., Leeper D.B., Cater J.R., Thistlethwaite A.J., Tupchong L., McFarlane J.D. Extracellular pH distribution in human tumors. Int. J. Hypertherm. 1995, 11:211-216.
31. Gerweck L.E., Seetharaman K. Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res. 1996, 56:1194-1198.
32. Helmlinger G., Sckell A., Dellian M., Forbes N.S., Jain R.K. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin. Cancer Res. 2002, 8:1284-1291.
33. Trevani S., Andonegui G., Giordano M., Lopez D., Gamberale R., Minucci F., Geffner J.R. Extracellular acidification induces human neutrophil activation. J. Immunol. 1999, 162:4849-4857.
34. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin. Cancer Res. 1999, 5:83-94.
35. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
36. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Payner R., Doran J., Young A.M., Burtles S., Kerr D.J. Hepatic drug targeting: phase 1 evaluation of polymer bound doxorubicin. J. Clin. Oncol. 2002, 1668-1676.
37. Ulbrich K., Etrych T., Chytil P., Jelinkova M., Rihova B. HPMA copolymers with pH-controlled release of doxorubicin In vitro cytotoxicity and in vivo antitumor activity. J. Control. Release 2003, 87:33-47.
38. Lee C.C., Gillies E.R., Fox M.E., Cramer A.T., Fréchet J.M.J., Dy E., Szoka F.C. A single dose of doxorubicin-functionalized bow-tie dendrimer cures mice bearing C-26 colon carcinomas. Proc. Natl. Acad. Sci. U. S. A. 2006, 45:16649-16654.
39. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., Greenfield R.S., Kaneko T., Firestone R.A. (6-Maleimidocaproyl)hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug. Chem. 1993, 4:521-527.
40. Mellman I., Fuchs R., Helenius A. Acidification of the endocytic and exocytic pathways. Annu. Rev. Biochem. 1986, 55:663-700.
41. Denny W.A. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol. 2010, 6:419-428.
42. Schellmann N., Deckert P.M., Bachran D., Fuchs H., Bachran C. Targeted enzyme prodrug therapies. Mini-Rev. Med. Chem. 2010, 10:887-904.
43. Sohn J.S., Jin J.I., Hess M., Jo B.W. Polymer prodrug approaches applied to paclitaxel. Polym. Chem. 2010, 1:778-792.
44. Kratz F., Müller I.A., Ryppa C., Warnecke A. Prodrug strategies in anticancer chemotherapy. ChemMedChem 2008, 3:20-53.
45. Carl P.L., Chakravarty P.K., Katzenellenbogen J.A. A novel connector linkage applicable in prodrug design. J. Med. Chem. 1981, 24:479-480.
46. Kroemer H., Gesson J., Koch M., Monneret C. Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Res. 1998, 58:1195-1201.
47. Tietze L.F., Schuster H.J., Schmuck K., Schuberth I., Alves F. Duocarmycin-based prodrugs for cancer prodrug monotherapy. Bioorg. Med. Chem. 2008, 16:6312-6318.
48. Senter P.D. Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. J. Fed. Am. Soc. Exp. Biol. 1990, 4:188-193.
49. Kratz F., W.A., Schmid B., Chung D.E., Gitzel M. Prodrugs of anthracyclines in cancer chemotherapy. Curr. Med. Chem. 2006, 13:477-523.
50. Dubowchik G.M., Firestone R.A. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin. Bioorg. Med. Chem. Lett. 1998, 8:3341-3346.
51. Leenders R.G.G., Damen E.W.P., Bijsterveld E.J.A., Scheeren H.W., Houba P.H.J., van der Meulen-Muileman I.H., Boven E., Haisma H.J. Novel anthracycline-spacer-[beta]-glucuronide,-[beta]-glucoside, and-[beta]-galactoside prodrugs for application in selective chemotherapy. Bioorg. Med. Chem. 1999, 7:1597-1610.
52. Madec-Lougerstay R., Florent J.C., Monneret C. Synthesis of self-immolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy. J. Chem. Soc. Perkin Trans. 1999, 1:1369-1376.
53. Irigoyen J.P., Munoz-Canoves P., Montero L., Koziczak M., Nagamine Y. The plasminogen activator system: biology and regulation. Cell. Mol. Life Sci. 1999, 56:104-132.
54. Wakselman M. 1,4-Eliminations and 1,6-eliminations from hydroxy-substituted and amino-substituted benzyl systems - chemical and biochemical applications. Nouv. J. Chem. 1983, 7:439-447.
55. Senter P.D., Pearce W.E., Greenfield R.S. Development of a drug-release strategy based on the reductive fragmentation of benzyl carbamate disulfides. J. Org. Chem. 1990, 55:2975-2978.
56. Shan D., Nicolaou M.G., Borchardt R.T., Wang B. Prodrug strategies based on intramolecular cyclization reactions. J. Pharm. Sci. 1997, 86:765-767.
57. Greenwald R.B., Choe Y.H., Conover C.D., Shum K., Wu D., Royzen M. Drug delivery systems based on trimethyl lock lactonization: poly(ethylene glycol) prodrugs of amino-containing compounds. J. Med. Chem. 2000, 43:475-487.
58. Tranoy-Opalinski I., Fernandes A., Thomas M., Gesson J.-P., Papot S. Design of self-immolative linkers for tumour-activated prodrug therapy. Anti-Cancer Agents Med. Chem. 2008, 8:618-637.
59. Saari W.S., Schwering J.E., Lyle P.A., Smith S.J., Engelhardt E.L. Cyclization-activated prodrugs. Basic carbamates of 4-hydroxyanisole. J. Med. Chem. 1990, 33:97-101.
60. Greenwald R.B., Conover C.D., Choe Y.H. Poly(ethylene glycol) conjugated drugs and prodrugs: a comprehensive review. Crit. Rev. Ther. Drug 2000, 17:101-161.
61. Schuster H.J., Krewer B., von Hof J.M., Schmuck K., Schuberth I., Alves F., Tietze L.F. Synthesis of the first spacer containing prodrug of a duocarmycin analogue and determination of its biological activity. Org. Biomol. Chem. 2010, 8:1833-1842.
62. Abu Ajaj K., Kratz F. Development of dual-acting prodrugs for circumventing multidrug resistance. Bioorg. Med. Chem. Lett. 2009, 19:995-1000.
63. Leu Y.-L., Chen C.-S., Wu Y.-J., Chern J.-W. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy. J. Med. Chem. 2008, 51:1740-1746.
64. Antczak C., Jaggi J.S., LeFave C.V., Curcio M.J., McDevitt M.R., Scheinberg D.A. Influence of the linker on the biodistribution and catabolism of actinium-225 self-immolative tumor-targeted isotope generators. Bioconjug. Chem. 2006, 17:1551-1560.
65. El Alaoui A., Saha N., Schmidt F., Monneret C., Florent J.-C. New taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg. Med. Chem. 2006, 14:5012-5019.
66. Toki B.E., Cerveny C.G., Wahl A.F., Senter P.D. Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs. J. Org. Chem. 2002, 67:1866-1872.
67. Zhang X.-B., Waibel M., Hasserodt J. An autoimmolative spacer allows first-time incorporation of a unique solid-state fluorophore into a detection probe for acyl hydrolases. Chem. Eur. J. 2010, 16:792-795.
68. Antunes I.F., Haisma H., Elsinga P.H., Dierckx R.A., de Vries E.F.J. Synthesis and evaluation of [18F]-FEAnGA as a PET tracer for b -glucuronidase activity. Bioconjug. Chem. 2010, 21:911-920.
69. Meyer Y., Richard J.-A., Delest B., Noack P., Renard P.-Y., Romieu A. A comparative study of the self-immolation of para-aminobenzyl alcohol and hemithioaminal-based linkers in the context of protease-sensitive fluorogenic probes. Org. Biomol. Chem. 2010, 8:1777-1780.
70. Louise-Leriche L., Paunescu E., Saint-Andre G., Baati R., Romieu A., Wagner A., Renard P.-Y. A HTS assay for the detection of organophosphorus nerve agent scavengers. Chem. Eur. J. 2010, 16:3510-3523.
71. Meyer Y., Richard J.A., Massonneau M., Renard P.Y., Romieu A. Development of a new nonpeptidic self-immolative spacer. Application to the design of protease sensing fluorogenic probes. Org. Lett. 2008, 10:1517-1520.
72. Zhu B., Zhang X., Jia H., Li Y., Liu H., Tan W. A highly selective ratiometric fluorescent probe for 1,4-dithiothreitol (DTT) detection. Org. Biomol. Chem. 2010, 8:1650-1654.
73. Richard J.-A., Meyer Y., Jolivel V., Massonneau M., Dumeunier R., Vaudry D., Vaudry H., Renard P.-Y., Romieu A. Latent fluorophores based on a self-immolative linker strategy and suitable for protease sensing. Bioconjug. Chem. 2008, 19:1707-1718.
74. Richard J.-A., Jean L., Romieu A., Massonneau M., Noack-Fraissignes P., Renard P.-Y. Chemiluminescent probe for the in vitro detection of protease activity. Org. Lett. 2007, 9:4853-4855.
75. Ho N.-H., Weissleder R., Tung C.-H. A self-immolative reporter for beta-galactosidase sensing. ChemBioChem 2007, 8:560-566.
76. Chen S., Zhao X., Chen J., Chen J., Kuznetsova L., Wong S.S., Ojima I. Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release. Bioconjug. Chem. 2010, 21:979-987.
77. Burke P.J., Senter P.D., Meyer D.W., Miyamoto J.B., Anderson M., Toki B.E., Manikumar G., Wani M.C., Kroll D.J., Jeffrey S.C. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug. Chem. 2009, 20:1242-1250.
78. Kumar S.K., Williams S.A., Isaacs J.T., Denmeade S.R., Khan S.R. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg. Med. Chem. 2007, 15:4973-4984.
79. Schmidt F., Florent J.-C., Monneret C., Straub R., Czech J., Gerken M., Bosslet K. Glucuronide prodrugs of hydroxy compounds for antibody directed enzyme prodrug therapy (ADEPT): a phenol nitrogen mustard carbamate. Bioorg. Med. Chem. Lett. 1997, 7:1071-1076.
80. Mauger A.B., Burke P.J., Somani H.H., Friedlos F., Knox R.J. Self-immolative prodrugs: candidates for antibody-directed enzyme prodrug therapy in conjunction with a nitroreductase enzyme. J. Med. Chem. 1994, 37:3452-3458.
81. Satyam A. Design and synthesis of releasable folate-drug conjugates using a novel heterobifunctional disulfide-containing linker. Bioorg. Med. Chem. Lett. 2008, 18:3196-3199.
82. Vlahov I.R., Vite G.D., Kleindl P.J., Wang Y., Santhapuram H.K.R., You F., Howard S.J., Kim S.H., Lee F.F.Y., Leamon C.P. Regioselective synthesis of folate receptor-targeted agents derived from epothilone analogs and folic acid. Bioorg. Med. Chem. Lett. 2010, 20:4578-4581.
83. de Groot F.M.H., Loos W.J., Koekkoek R., van Berkom L.W.A., Busscher G.F., Seelen A.E., Albrecht C., de Brujin P., Scheeren H.W. Elongated multiple electronic cascade and cyclization spacer systems in activatible anticancer prodrugs for enhanced drug release. J. Org. Chem. 2001, 66:8815-8830.
84. Weinstain R., Segal E., Satchi-Fainaro R., Shabat D. Real-time monitoring of drug release. Chem. Commun. 2010, 46:553-555.
85. Perry-Feigenbaum R., Baran P.S., Shabat D. The pyridinone-methide elimination. Org. Biomol. Chem. 2009, 7:4825-4828.
86. El Alaoui A., Schmidt F., Monneret C., Florent J.C. Protecting groups for glucuronic acid: application to the synthesis of new paclitaxel (taxol) derivatives. J. Org. Chem. 2006, 71:9628-9636.
87. Devy L., de Groot F.M.H., Blacher S., Hajitou A., Beusker P.H., Scheeren H.W., Foidart J.M., Noel A. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity. J. Fed. Am. Soc. Exp. Biol. 2004, 18:565-567.
88. Warnecke A., Kratz F. 2,4-Bis(hydroxymethyl)aniline as a building block for oligomers with self-eliminating and multiple release properties. J. Org. Chem. 2008, 73:1546-1552.
89. Vögtle F., Richardt G., Werner N. Dendrimer chemistry: concepts, syntheses, properties, applications 2009, WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
90. Fréchet J.M.J., Tomalia D.e. Dendrimers and other Dendritic Polymers 2001, Wiley and Sons, Chichester and New York.
91. Boas U., Christensen J.B., Heegard P.M.H. Dendrimers in medicine and biotechnology: new molecular tools 2006, The Royal Society of Chemistry, Cambridge.
92. Majoros I., Baker J.R. Dendrimer-based nanomedicine, in 2008, Pan Stanford Publishing Pte. Ltd., Singapore.
93. de Groot F.M.H., Albrecht C., Koekkoek R., Beusker P.H., Scheeren H.W. "Cascade release dendrimers" liberate all end groups upon a single triggering event in the dendritic core. Angew. Chem. Int. Ed. 2003, 42:4490-4494.
94. Li S., Szalai M.L., Kevwitch R.M., McGrath D.V. Dendrimer disassembly by benzyl ether depolymerization. J. Am. Chem. Soc. 2003, 125:10156-10157.
95. Amir R.J., Pessah N., Shamis M., Shabat D. Self-immolative dendrimers. Angew. Chem. Int. Ed. 2003, 42:4494-4499.
96. Szalai M.L., Kevwitch R.M., McGrath D.V. Geometric disassembly of dendrimers: dendritic amplification. J. Am. Chem. Soc. 2003, 125:15688-15689.
97. Szalai M.L., McGrath D.V. Phototriggering of geometric dendrimer disassembly: an improved synthesis of 2,4-bis(hydroxymethyl)phenol based dendrimers. Tetrahedron 2004, 60:7261-7266.
98. Ortiz A., Shanahan C.S., Sisk D.T., Perera S.C., Rao P., McGrath D.V. Improved iterative synthesis of linearly disassembling dendrons. J. Org. Chem. 2010, 75:6154-6162.
99. Polaske N.W., Szalai M.L., Shanahan C.S., McGrath D.V. Convergent synthesis of geometrically disassembling dendrimers using Cu(I)-catalyzed C-O bond formation. Org. Lett. 2010, 12:4944-4947.
100. Shamis M., Lode H.N., Shabat D. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. J. Am. Chem. Soc. 2004, 126:1726-1731.
101. Haba K., Popkov M., Shamis M., Lerner R.A., Barbas C.F., Shabat D. Single-triggered trimeric prodrugs. Angew. Chem. Int. Ed. 2005, 44:716-720.
102. Sagi A., Segal E., Satchi-Fainaro R., Shabat D. Remarkable drug-release enhancement with an elimination-based AB3 self-immolative dendritic amplifier. Bioorg. Med. Chem. 2007, 15:3720-3727.
103. Perry R., Amir R.J., Shabat D. Substituent-dependent disassembly of self-immolative dendrimers. N.J. Chem. 2007, 31:1307-1312.
104. Erez R., Segal E., Miller K., Satchi-Fainaro R., Shabat D. Enhanced cytotoxicity of a polymer-drug conjugate with triple payload of paclitaxel. Bioorg. Med. Chem. 2009, 17:4327-4335.
105. Gopin A., Ebner S., Attali B., Shabat D. Enzymatic activation of second-generation dendritic prodrugs: conjugation of self-immolative dendrimers with poly (ethylene glycol) via click chemistry. Bioconjug. Chem. 2006, 17:1432-1440.
106. Avital-Shmilovici M., Shabat D. Enzymatic activation of hydrophobic self-immolative dendrimers: the effect of reporters with ionizable functional groups. Bioorg. Med. Chem. Lett. 2009, 19:3959-3962.
107. Amir R.J., Shabat D. Self-immolative dendrimer biodegradability by multi-enzymatic triggering. Chem. Commun. 2004, 40:1614-1615.
108. Amir R.J., Popkov M., Lerner R.A., Barbas C.F., Shabat D. Prodrug activation gated by a molecular "OR" logic trigger. Angew. Chem. Int. Ed. 2005, 44:4378-4381.
109. Shamis M., Shabat D. Single-triggered AB6 self-immolative dendritic amplifiers. Chem. Eur. J. 2007, 13:4523-4528.
110. Danieli E., Shabat D. Molecular probe for enzymatic activity with dual output. Bioorg. Med. Chem. 2007, 15:7318-7324.
111. Amir R.J., Danieli E., Shabat D. Receiver-amplifier, self-immolative dendritic device. Chem. Eur. J. 2007, 2007:812-821.
112. Sella E., Shabat D. Self-immolative dendritic probe for direct detection of triacetone triperoxide. Chem. Commun. 2008, 2008:5701-5703.
113. Sella E., Shabat D. Dendritic chain reaction. J. Am. Chem. Soc. 2009, 131:9934-9936.
114. Avital-Shmilovici M., Shabat D. Dendritic chain reaction: responsive release of hydrogen peroxide upon generation and enzymatic oxidation of methanol. Bioorg. Med. Chem. 2010, 18:3643-3647.
115. Sella E., Lubelski A., Klafter J., Shabat D. Two-component dendritic chain reactions: experiment and theory. J. Am. Chem. Soc. 2010, 132:3945-3952.
116. Sella E., Weinstain R., Erez R., Burns N.Z., Baran P.S., Shabat D. Sulfhydryl-based dendritic chain reaction. Chem. Commun. 2010, 46:6575-6577.
117. Sagi A., Weinstain R., Karton N., Shabat D. Self-immolative polymers. J. Am. Chem. Soc. 2008, 130:5434-5435.
118. Weinstain R., Baran P.S., Shabat D. Activity-linked labeling of enzymes by self-immolative polymers. Bioconjug. Chem. 2009, 20:1783-1791.
119. Weinstain R., Sagi A., Karton N., Shabat D. Self-immolative comb-polymers: multiple release of side-reporters by a single stimulus event. Chem. Eur. J. 2008, 14:6857-6861.
120. DeWit M.A., Gillies E.R. A cascade degradable polymer based on alternating cyclization and elimination reactions. J. Am. Chem. Soc. 2009, 131:18327-18334.
121. Esser-Kahn A.P., Sottos N.R., White S.R., Moore J.S. Programmable microcapsules from self-immolative polymers. J. Am. Chem. Soc. 2010, 132:10266-10268.
122. Fomina N., McFearin C., Sermsakdi M., Edigin O., Almutairi A. UV and near-IR triggered release from polymeric nanoparticles. J. Am. Chem. Soc. 2010, 132:9540-9542.
123. Greenwald R.B., Pendri A., Conover C.D., Zhao H., Choe Y.H., Martinez A., Shum K., Guan S. Drug delivery systems employing 1,4- or 1,6-elimination: poly(ethylene glycol) prodrugs of amine-containing compounds. J. Med. Chem. 1999, 42:3657-3667.
124. Monks T.J., Jones D.C. The metabolism and toxicity of quinones, quinonimines, quinone methides, and quinone-thioethers. Curr. Drug Metab. 2002, 3:425-438.
125. Guyton K.Z., Thompson J.A., Kensler T.W. Role of quinone methide in the in vitro toxicity of the skin tumor propoter butylated hydroxytoluene hydroperoxide. Chem. Res. Toxicol. 1993, 6:731-738.
126. Thompson D.C., Barhoumi R., Burghardt R.C. Comparative toxicity of eugenol and its quinone methide metabolite in cultured liver cells using kinetic fluorescence bioassays. Toxicol. Appl. Pharmacol. 1998, 149:55-63.
127. DeWit M.A., Beaton A., Gillies E.R. A reduction sensitive cascade biodegradable linear polymer. J. Polym. Sci. Part A: Polym. Chem. 2010, 48:3977-3985.
128. DeWit M.A., Gillies E.R. Design, synthesis, and cyclization of 4-aminobutyric acid derivatives: potential candidates as self-immolative spacers. Org. Biomol. Chem. 2011, 9:1846-1854.